BeiGene CEO John Oyler steps up to the Big Phar­ma league with $16M in comp as shares sour

BeiGene’s com­pen­sa­tion re­port is out — and it puts founder, chair­man and CEO John Oyler in a very nice spot at the head of the ma­tur­ing biotech with glob­al as­pi­ra­tions. The salary puts Oyler on par with many Big Phar­ma ex­ecs, even as shares of $BGNE are down more than 50% over the last 12 months.

Oyler’s com­pen­sa­tion pack­age rang up at $16,748,546 last year, which puts the head of the glob­al biotech just be­low the top range of biotech/phar­ma CEO com­pen­sa­tion — and over­all bet­ter for Oyler than in pre­vi­ous years, where he made $14.4 mil­lion in 2020 and $12.5 mil­lion in 2019.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER